A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to evaluate the safety and tolerability of lecanemab at
sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).